ROS1 and non-small cell lung carcinoma: Crizotinib, the first ALK inhibitor approved by the U.S. Food and Drug Administration (FDA) in 2011, targets ALK and ROS1 to treat metastatic NSCLC and ALK-positive myofibroblastic tumors [55,56].